Carbahal Olsen Financial Services Group LLC Invests $312,000 in Johnson & Johnson (NYSE:JNJ)

Carbahal Olsen Financial Services Group LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, Holdings Channel reports. The fund acquired 2,155 shares of the company’s stock, valued at approximately $312,000. Johnson & Johnson comprises about 0.3% of Carbahal Olsen Financial Services Group LLC’s investment portfolio, making the stock its 24th largest holding.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock valued at $8,321,881,000 after buying an additional 1,561,036 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $4,390,037,000. Wellington Management Group LLP boosted its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after buying an additional 431,205 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Johnson & Johnson by 6.5% in the 4th quarter. Invesco Ltd. now owns 19,126,079 shares of the company’s stock valued at $2,766,014,000 after purchasing an additional 1,171,975 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Raymond James cut their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Finally, Barclays reduced their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $171.82.

Johnson & Johnson Price Performance

JNJ stock opened at $157.42 on Friday. The business has a 50 day moving average price of $159.49 and a 200 day moving average price of $155.03. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.